Oxford Biomedica names chief development officer
This article was originally published in Scrip
Executive Summary
Oxford BioMedica, a gene and cell therapy company, has named its non-executive director Dr Paul Blake to its executive management team as chief development officer – effective 1 September 2014. Dr Blake joined the board of Oxford BioMedica in January 2010 and will retain his seat alongside his new position. Most recently, Dr Blake was senior vice-president and chief medical officer of Æterna Zentaris, a global biopharmaceutical company focused on oncology and endocrine therapy.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.